Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
about
Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
P2860
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Randomized Phase 3 Trial of Om ...... 2-Infected Japanese Patients.
@en
type
label
Randomized Phase 3 Trial of Om ...... 2-Infected Japanese Patients.
@en
prefLabel
Randomized Phase 3 Trial of Om ...... 2-Infected Japanese Patients.
@en
P2093
P2860
P1433
P1476
Randomized Phase 3 Trial of Om ...... 2-Infected Japanese Patients.
@en
P2093
Carolyn Setze
Fumitaka Suzuki
Hidenori Toyoda
Hiromitsu Kumada
Katia Alves
Kazuaki Chayama
Lino Rodrigues
Margaret Burroughs
P2860
P2888
P304
P356
10.1007/S12325-017-0506-Y
P407
P577
2017-05-23T00:00:00Z
P6179
1085562750